The U.S. Patent and Trademark Office issued a new patent to
Arena Pharmaceuticals, Inc.
) for its pain candidate APD371 (U.S. Patent No. 8,778,950). APD371
is an agonist of the cannabinoid receptor 2 (CB2). The patent,
entitled Cannabinoid Receptor Modulators, along with other patents
is expected to protect APD371 at least till 2030.
Arena Pharma owns several patents and patent applications which
cover composition of matter and methods of treatment for APD371 and
related compounds. The company has filed patent applications for
APD371 in several countries including the U.S., Europe, Japan and
In Dec 2013, Arena Pharma initiated dosing in a randomized,
double-blind, placebo-controlled phase I study (n = 56) to evaluate
the safety, tolerability and pharmacokinetics of single-ascending
doses of APD371 in healthy adults.
As per company sources, approximately 100 million adults suffer
from chronic pain in the U.S. In 2010, the worldwide pain
management therapeutics market was estimated to be around $29
billion. Pain relievers like aspirin, acetaminophen and ibuprofen
are some of the most commonly prescribed treatments.
Arena Pharma's pipeline includes several other candidates including
APD811 (pulmonary arterial hypertension, phase II expected to start
shortly), APD334 (autoimmune diseases, ongoing), and temanogreal
(thrombotic diseases, phase I completed). As of now, Arena Pharma's
growth is highly dependent on its sole marketed product Belviq for
Arena Pharma carries a Zacks Rank #4 (Sell). Some better-ranked
stocks in the health care sector include
BioMarin Pharmaceutical Inc.
Biogen Idec Inc.
), each carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BIOMARIN PHARMA (BMRN): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
ARENA PHARMA (ARNA): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
To read this article on Zacks.com click here.